Adjuvant Belzutifan Combo Is ‘Practice Changing’ in RCC

by | Mar 4, 2026 | Health

Spread the love
Adding belzutifan to standard adjuvant pembrolizumab cut the risk for recurrence or death in patients with resected clear cell renal cell carcinoma.
Medscape Medical News

Written By

Written by Albert Pham, News Curator and Blogger

Related Posts

0 Comments